N
Nucleix
Developing cancer diagnostic panels based on epigenetic bio markers
About Nucleix
Nucleix is a health-tech startup that operates in the cancer detection market. The company's primary focus is on early detection of cancer, with a particular emphasis on bladder and lung cancer. Their innovative approach involves the use of liquid biopsy assays, a type of blood test that can detect cancer cells or DNA from cancer cells. This method is non-invasive and can be used to detect cancer at an early stage, which significantly increases the chances of successful treatment.
Read full description
Nucleix's flagship products are Bladder EpiCheck® and a blood test for early-stage lung cancer detection. Bladder EpiCheck® is available in Europe for primary and recurrent bladder cancer and upper tract urinary cancer, and it has also received FDA 510(k) clearance for bladder cancer recurrence in the United States. The lung cancer blood test is designed for high-risk individuals, providing a simple and effective way to monitor for early signs of the disease.
The company's business model revolves around partnering with medical centers, organizations, and laboratories worldwide. By offering a seamless testing option that delivers highly accurate and sensitive results, Nucleix provides a valuable service to both patients and the healthcare system. The company generates revenue through the sale of its testing services to these healthcare providers.
In terms of future growth, Nucleix's R&D team has the capabilities and experience to develop additional liquid biopsy assays for other types of cancer, which could significantly expand the company's market reach.
At a glance
- Status
- Operational
- Founded
- 2008
- Headquarters
- Rehovot, Israel
- Employees
- 73
- Open positions
- None listed
- Dealroom signal
- 74.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Predictive Analytics, Developer Tools, Biotechnology, Oncology, DNA, Genetics and genomics, Biochemical, Non-Invasive medical devices and treatments, Spinout
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Jan 2022 | $22M | $275M | Sands Capital Management | ↗ |
| LATE VCOther financing | Apr 2021 | $55M | $220M | BlackRock · Aurum Ventures · Lilly Asia Ventures · OCI Bio Investments | — |
Growth signals
Latest recorded traffic for Nucleix is 450 monthly website visits, down 75% over the last three months. Nucleix's team grew 4.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
Zohar Zisapel
OrbiMed
Aurum Ventures
European Innovation Council
Series B and later8 investors entered at this stage
RA Capital Management
BlackRock
Lilly Asia Ventures- OIOCI Bio Investments
DSC Investment
LYFE Capital
MILFAM
Sands Capital Management
Other known investors1 additional known investor
Weizmann Institute of Science
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nucleix on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nucleix’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.